Genomic imprinting of insulin-like growth factor 2 (IGF-2) in chronic synovitis
Möller, B, Kerschbaumer, G, Komor, M, Kerschbaumer, F, Ottmann, O.G, Hoelzer, D, Hofmann, W.K
Published in Growth hormone & IGF research (01.12.2007)
Published in Growth hormone & IGF research (01.12.2007)
Get full text
Journal Article
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
Giles, F J, le Coutre, P D, Pinilla-Ibarz, J, Larson, R A, Gattermann, N, Ottmann, O G, Hochhaus, A, Radich, J P, Saglio, G, Hughes, T P, Martinelli, G, Kim, D-W, Novick, S, Gillis, K, Fan, X, Cortes, J, Baccarani, M, Kantarjian, H M
Published in Leukemia (01.01.2013)
Published in Leukemia (01.01.2013)
Get full text
Journal Article
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia
Pfeifer, H, Wassmann, B, Bethge, W, Dengler, J, Bornhäuser, M, Stadler, M, Beelen, D, Vucinic, V, Burmeister, T, Stelljes, M, Faul, C, Dreger, P, Kiani, A, Schäfer-Eckart, K, Schwerdtfeger, R, Lange, E, Kubuschok, B, Horst, H A, Gramatzki, M, Brück, P, Serve, H, Hoelzer, D, Gökbuget, N, Ottmann, O G
Published in Leukemia (01.06.2013)
Published in Leukemia (01.06.2013)
Get full text
Journal Article
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
DeAngelo, D J, Spencer, A, Bhalla, K N, Prince, H M, Fischer, T, Kindler, T, Giles, F J, Scott, J W, Parker, K, Liu, A, Woo, M, Atadja, P, Mishra, K K, Ottmann, O G
Published in Leukemia (01.08.2013)
Published in Leukemia (01.08.2013)
Get full text
Journal Article
Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008
BRÜGGEMANN, M, SCHRAUDER, A, BIONDI, A, CAVE, H, DOMBRET, H, FIELDING, A. K, FOA, R, GÖKBUGET, N, GOLDSTONE, A. H, GOULDEN, N, HENZE, G, HOELZER, D, RAFF, T, JANKA-SCHAUH, G. E, MACINTYRE, E. A, PIETERS, R, RAMBALDI, A, RIBERA, J.-M, SCHMIEGELOW, K, SPINELLI, O, STARY, J, VON STACKELBERG, A, KNEBA, M, PFEIFER, H, SCHRAPPE, M, VAN DONGEN, Jjm, DWORZAK, M, OTTMANN, O. G, ASNAFI, V, BARUCHEL, A, BASSAN, R, BENOIT, Y
Published in Leukemia (01.03.2010)
Published in Leukemia (01.03.2010)
Get full text
Journal Article
PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation
Mian, A A, Rafiei, A, Haberbosch, I, Zeifman, A, Titov, I, Stroylov, V, Metodieva, A, Stroganov, O, Novikov, F, Brill, B, Chilov, G, Hoelzer, D, Ottmann, O G, Ruthardt, M
Published in Leukemia (01.05.2015)
Published in Leukemia (01.05.2015)
Get full text
Journal Article
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia
Giles, F J, Swords, R T, Nagler, A, Hochhaus, A, Ottmann, O G, Rizzieri, D A, Talpaz, M, Clark, J, Watson, P, Xiao, A, Zhao, B, Bergstrom, D, Le Coutre, P D, Freedman, S J, Cortes, J E
Published in Leukemia (01.01.2013)
Published in Leukemia (01.01.2013)
Get full text
Journal Article
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
PFEIFER, H, LANGE, T, WUNDERLE, L, SERVE, H, BRÜCK, P, SCHMIDT, A, HOELZER, D, OTTMANN, O. G, WYSTUB, S, WASSMANN, B, MAIER, J, BINCKEBANCK, A, GIAGOUNIDIS, A, STELLJES, M, SCHMALZING, M, DÜHRSEN, U
Published in Leukemia (01.07.2012)
Published in Leukemia (01.07.2012)
Get full text
Journal Article
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase
GILES, F. J, KANTARJIAN, H. M, HOCHHAUS, A, OTTMANN, O. G, LE COUTRE, P. D, BACCARANI, M, MAHON, F.-X, BLAKESLEY, R. E, GALLAGHER, N. J, GILLIS, K, GOLDBERG, S. L, LARSON, R. A
Published in Leukemia (01.05.2012)
Published in Leukemia (01.05.2012)
Get full text
Journal Article
Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia
Ottmann, O G, Larson, R A, Kantarjian, H M, le Coutre, P D, Baccarani, M, Hochhaus, A, Kim, D W, Fan, X, Novick, S, Giles, F J
Published in Leukemia (01.06.2013)
Published in Leukemia (01.06.2013)
Get full text
Journal Article
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia
SINGER, J. B, SHOU, Y, OTTMANN, O. G, GILES, F, KANTARJIAN, H. M, HSU, Y, ROBEVA, A. S, RAE, P, WEITZMAN, A, MEYER, J. M, DUGAN, M
Published in Leukemia (01.11.2007)
Published in Leukemia (01.11.2007)
Get full text
Journal Article
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients
Platzbecker, U, Al-Ali, H K, Gattermann, N, Haase, D, Janzen, V, Krauter, J, Götze, K, Schlenk, R, Nolte, F, Letsch, A, Ottmann, O G, Kündgen, A, Lübbert, M, Germing, U, Wermke, M, Reinhard, H, Weiss, C, Lieder, K, Ehninger, G, Leismann, O, Giagounidis, A
Published in Leukemia (01.03.2014)
Published in Leukemia (01.03.2014)
Get full text
Journal Article
Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome
BOEHRER, S, ADES, L, TAILLER, M, OLAUSSEN, K. A, GARDIN, C, ECLACHE, V, DE BOTTON, S, THEPOT, S, FENAUX, P, KROEMER, G, TAJEDDINE, N, HOFMANN, W. K, KRIENER, S, BUG, G, OTTMANN, O. G, RUTHARDT, M, GALLUZZI, L, FOUASSIER, C
Published in Oncogene (04.06.2009)
Published in Oncogene (04.06.2009)
Get full text
Journal Article
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
Jabbour, E, le Coutre, P D, Cortes, J, Giles, F, Bhalla, K N, Pinilla-Ibarz, J, Larson, R A, Gattermann, N, Ottmann, O G, Hochhaus, A, Hughes, T P, Saglio, G, Radich, J P, Kim, D-W, Martinelli, G, Reynolds, J, Woodman, R C, Baccarani, M, Kantarjian, H M
Published in Leukemia (01.04.2013)
Published in Leukemia (01.04.2013)
Get full text
Journal Article
The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR ABL
MIAN, A. A, SCHÜLL, M, ZHAO, Z, OANCEA, C, HUNDERTMARK, A, BEISSERT, T, OTTMANN, O. G, RUTHARDT, M
Published in Leukemia (01.09.2009)
Published in Leukemia (01.09.2009)
Get full text
Journal Article
High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations
Pursche, S., Ottmann, O.G., Ehninger, G., Schleyer, E.
Published in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (01.06.2007)
Published in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (01.06.2007)
Get full text
Journal Article
Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)
WASSMANN, B, PFEIFER, H, SCHEURING, U, KLEIN, S. A, GÖKBUGET, N, BINCKEBANCK, A, MARTIN, H, GSCHAIDMEIER, H, HOELZER, D, OTTMANN, O. G
Published in Leukemia (01.12.2002)
Published in Leukemia (01.12.2002)
Get full text
Journal Article
Dasatinib (SPRYCEL®) Efficacy and Safety in Patients (pts) with Chronic Myelogenous Leukemia in Lymphoid (CML-LB) or Myeloid Blast (CML-MB) Phase Who Are Imatinib-Resistant (Im-r) or -Intolerant (Im-i)
Martinelli, Giovanni, Hochhaus, A., Coutre, S., Apperley, J.F., Shah, N., Gollerkeri, A., Agarwal, P., Ottmann, O.G.
Published in Blood (16.11.2006)
Published in Blood (16.11.2006)
Get full text
Journal Article